XT
CPRX icon

XTX Topco’s Catalyst Pharmaceutical CPRX Stock Holding History

XTX Topco’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,623
Closed -$282K – 2483
2025
Q1 		$282K Sell
11,623
-15,179
-57% -$342K 0.01% 1457
2024
Q4 		$559K Buy
26,802
+7,508
+39% +$161K 0.05% 678
2024
Q3 		$384K Buy
19,294
+8,160
+73% +$151K 0.03% 1020
2024
Q2 		$172K Buy
11,134
+773
+7% +$12K 0.01% 1294
2024
Q1 		$165K Buy
+10,361
New +$156K 0.02% 1233
2023
Q4 		– Sell
-13,227
Closed -$155K – 1677
2023
Q3 		$155K Buy
+13,227
New +$177K 0.03% 1097
2022
Q4 		– Sell
-22,534
Closed -$289K – 1183
2022
Q3 		$289K Buy
+22,534
New +$267K 0.07% 529
2022
Q1 		– Sell
-19,253
Closed -$130K – 712
2021
Q4 		$130K Buy
19,253
+6,925
+56% +$45.5K 0.07% 427
2021
Q3 		$65K Sell
12,328
-6,888
-36% -$37.7K 0.02% 587
2021
Q2 		$110K Buy
+19,216
New +$99.2K 0.04% 648

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

XTX Topco's CPRX Position: Q2 2025 in Review

XTX Topco sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 11,623 shares — an estimated $282K sold.

XTX Topco first reported a position in CPRX in Q2 2021 and held it in 10 quarters. The position peaked at $559K in Q4 2024. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

  • XTX Topco reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • XTX Topco sold 11,623 Catalyst Pharmaceutical shares in Q2 2025, an estimated $282K.
  • XTX Topco first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 10 quarters.
  • XTX Topco's Catalyst Pharmaceutical position peaked at $559K in Q4 2024.
  • 365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on XTX Topco's 13F filing for Q2 2025, filed 12 Aug 2025.